Anixa Biosciences, Inc. ANIX
Set alert
As of Nov 2, 2:24 PM ET
- YTD
- -3.45%
- 1 year
- -27.06%
- Open
- 3.14
- Prev close
- 3.12
- Mkt cap
- 104.99M
- Vol
- 98.48K
- Avg vol
- 278.49K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.01
- High
- 3.15
- Forward P/E
- -7.17
- Beta
- 0.85
- Short ratio
- 3.03
- Inst. own
- 17.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 21, 2025
- 50-d avg
- 3.17
- 200-d avg
- 3.04
- 1y target
- 8.50
News
6 days ago defenseworld.net
Anixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average – Time to Sell?
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.97 and traded as low as…
-
1 week ago benzinga.com
Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth
1 week ago prnewswire.com
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities…
2 weeks ago prnewswire.com
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")…
-
4 weeks ago benzinga.com
Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1,
4 weeks ago prnewswire.com
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No…
-
1 month ago benzinga.com
Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer
The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on…
1 month ago prnewswire.com
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg…
1 month ago defenseworld.net
Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were acquired at an…
1 month ago defenseworld.net
Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, September 24th. The shares were…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.
-
1 month ago benzinga.com
IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global…
1 month ago prnewswire.com
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global…
1 month ago prnewswire.com
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…
-
1 month ago benzinga.com
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of…
1 month ago prnewswire.com
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…
2 months ago prnewswire.com
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026…
-
2 months ago benzinga.com
Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the…
2 months ago prnewswire.com
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy,…
2 months ago prnewswire.com
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months…
3 months ago zacks.com
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
3 months ago zacks.com
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
-
3 months ago benzinga.com
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of
3 months ago prnewswire.com
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast…
-
3 months ago benzinga.com
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in
3 months ago prnewswire.com
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg…
-
4 months ago benzinga.com
Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual
4 months ago prnewswire.com
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual…
-
4 months ago benzinga.com
Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy
4 months ago prnewswire.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy,…
4 months ago zacks.com
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
4 months ago benzinga.com
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of…
-
5 months ago benzinga.com
Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Technology
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancerSAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa…
-
5 months ago benzinga.com
Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations…
-
6 months ago benzinga.com
Anixa Biosciences Receives Patent From Mexican Institute Of Industrial Property For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial…
-
6 months ago benzinga.com
Anixa Biosciences Reports Survival Data For Lira-cel In Phase 1 Trial At ISCT 2026 Conference
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")…
-
7 months ago benzinga.com
Anixa Biosciences Enters Into Development And Manufacturing Agreement With Cytovance Biologics To Produce cGMP Clinical Materials For Planned Phase 2 Clinical Trial Of Breast Cancer Vaccine
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participantsSAN JOSE, Calif., April 1,…
-
7 months ago benzinga.com
Anixa Biosciences To Present Ovarian Cancer CAR-T Therapy Clinical Trial At 2026 SGO Annual Meeting
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial statusSAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or…
-
7 months ago benzinga.com
Anixa Biosciences Receives South Korean Patent Allowance For Breast Cancer Vaccine Technology Licensed From Cleveland Clinic
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExpands global intellectual property coverage in markets with increasing breast cancer incidence rates and…
-
8 months ago benzinga.com
Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higherTrial expansion reflects growing…
8 months ago benzinga.com
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.
-
8 months ago benzinga.com
EXCLUSIVE: Anixa Biosciences Reports Patient Data In Ovarian Cancer CAR-T Trial After Regulatory Approval; Says 'Multiple patients substantially exceed expected survival at low dose levels'
The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer, who have failed standard of care chemotherapy, and progressed after two or more prior therapies. To date, twelve…
-
9 months ago benzinga.com
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
-
9 months ago benzinga.com
Anixa Biosciences Says USAN Council Approves liraltagene autoleucel For Non-Proprietary Name Of Company's FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names…
-
9 months ago benzinga.com
Anixa Biosciences Announces U.S. Adopted Names Council Approves Its Non-Proprietary Name For Its CAR-T Therapy For Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.